Market Closed -
Nasdaq
04:00:01 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
4.29
USD
|
-2.50%
|
|
+5.15%
|
+28.06%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
505.1
|
495
|
234.6
|
36.52
|
258.7
|
489.1
|
-
|
-
|
Enterprise Value (EV)
1 |
466.2
|
398.1
|
153.8
|
5.945
|
208.8
|
284.5
|
330.9
|
355.6
|
P/E ratio
|
-7.68
x
|
-5.14
x
|
-2.17
x
|
-0.35
x
|
-2.36
x
|
-3.35
x
|
-9.42
x
|
74.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
25.9
x
|
101
x
|
10.7
x
|
3.72
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
20.9
x
|
58.8
x
|
7.25
x
|
2.71
x
|
EV / EBITDA
|
-10.2
x
|
-4.21
x
|
-1.46
x
|
-0.07
x
|
-3.25
x
|
-3.09
x
|
-5.4
x
|
10.7
x
|
EV / FCF
|
-12.8
x
|
-5.09
x
|
-1.7
x
|
-
|
-
|
-3.49
x
|
-8.47
x
|
4.9
x
|
FCF Yield
|
-7.79%
|
-19.6%
|
-59%
|
-
|
-
|
-28.6%
|
-11.8%
|
20.4%
|
Price to Book
|
15.5
x
|
6.04
x
|
3.75
x
|
8.99
x
|
-16.6
x
|
2.7
x
|
4.43
x
|
4.95
x
|
Nbr of stocks (in thousands)
|
18,515
|
22,488
|
26,216
|
48,059
|
77,229
|
114,267
|
-
|
-
|
Reference price
2 |
27.28
|
22.01
|
8.950
|
0.7600
|
3.350
|
4.280
|
4.280
|
4.280
|
Announcement Date
|
3/13/20
|
3/18/21
|
3/10/22
|
3/23/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
9.993
|
4.837
|
45.66
|
131.4
|
EBITDA
1 |
-45.58
|
-94.47
|
-105.2
|
-82.51
|
-64.18
|
-92.15
|
-61.23
|
33.36
|
EBIT
1 |
-45.58
|
-94.47
|
-105.6
|
-82.95
|
-64.54
|
-90.8
|
-61.17
|
16.57
|
Operating Margin
|
-
|
-
|
-
|
-
|
-645.8%
|
-1,877.15%
|
-133.97%
|
12.61%
|
Earnings before Tax (EBT)
1 |
-45.51
|
-93.96
|
-105.6
|
-82.51
|
-119.8
|
-190.8
|
-48.08
|
34.02
|
Net income
1 |
-45.51
|
-93.96
|
-105.6
|
-82.51
|
-119.8
|
-163.4
|
-45.66
|
34.02
|
Net margin
|
-
|
-
|
-
|
-
|
-1,198.47%
|
-3,378.07%
|
-100.01%
|
25.89%
|
EPS
2 |
-3.550
|
-4.280
|
-4.120
|
-2.180
|
-1.420
|
-1.279
|
-0.4541
|
0.0577
|
Free Cash Flow
1 |
-36.31
|
-78.21
|
-90.73
|
-
|
-
|
-81.42
|
-39.08
|
72.61
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-1,683.17%
|
-85.59%
|
55.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
217.63%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
213.43%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/13/20
|
3/18/21
|
3/10/22
|
3/23/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
10.66
|
-
|
-
|
9.993
|
0.19
|
3.333
|
0.0877
|
1.431
|
-
|
-
|
EBITDA
1 |
-27.01
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-21
|
-20.59
|
-22.97
|
-24.36
|
-23.72
|
-
|
-
|
EBIT
1 |
-27.11
|
-23.1
|
-21.52
|
-19.36
|
-18.97
|
-10.86
|
-17.18
|
-15.5
|
-21.01
|
-21.09
|
-24.34
|
-26.37
|
-26.69
|
-24.36
|
-16.82
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-101.86%
|
-
|
-
|
-210.23%
|
-11,101.58%
|
-730.08%
|
-30,076.42%
|
-1,865.95%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-27.16
|
-23.12
|
-25.86
|
-19.1
|
-14.43
|
-10.14
|
-29.58
|
-42.37
|
-37.68
|
-83.94
|
-31.13
|
-40.73
|
-34.88
|
-23.39
|
-15.98
|
Net income
1 |
-27.16
|
-23.12
|
-25.86
|
-19.1
|
-14.43
|
-10.14
|
-29.58
|
-42.37
|
-37.68
|
-83.94
|
-21.79
|
-30.34
|
-27.25
|
-20.3
|
-13.86
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-95.09%
|
-
|
-
|
-377.05%
|
-44,177.89%
|
-653.58%
|
-34,611.22%
|
-1,905.13%
|
-
|
-
|
EPS
2 |
-1.040
|
-0.8800
|
-0.9600
|
-0.4000
|
-0.1600
|
-0.1800
|
-0.3700
|
-0.4700
|
-0.3300
|
-0.6700
|
-0.1797
|
-0.2472
|
-0.2188
|
-0.1500
|
-0.1000
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/12/22
|
8/12/22
|
11/9/22
|
3/23/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/6/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
38.9
|
96.8
|
80.8
|
30.6
|
49.9
|
205
|
158
|
133
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-36.3
|
-78.2
|
-90.7
|
-
|
-
|
-81.4
|
-39.1
|
72.6
|
ROE (net income / shareholders' equity)
|
-
|
-164%
|
-146%
|
-248%
|
-
|
-97.5%
|
-48.3%
|
-11%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
1.760
|
3.640
|
2.390
|
0.0800
|
-0.2000
|
1.580
|
0.9700
|
0.8600
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
64.2
|
-
|
0.05
|
0.15
|
0.66
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
1.13%
|
0.34%
|
0.51%
|
Announcement Date
|
3/13/20
|
3/18/21
|
3/10/22
|
3/23/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
4.28
USD Average target price
11.4
USD Spread / Average Target +166.36% Consensus |
1st Jan change
|
Capi.
|
---|
| +28.06% | 489M | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B | | +77.64% | 8.87B |
Bio Therapeutic Drugs
|